4,000,000 Shares of Common Stock DIAMEDICA THERAPEUTICS INC. UNDERWRITING AGREEMENTUnderwriting Agreement • August 10th, 2020 • DiaMedica Therapeutics Inc. • Pharmaceutical preparations • New York
Contract Type FiledAugust 10th, 2020 Company Industry JurisdictionDiaMedica Therapeutics Inc., a corporation organized and existing under the laws of British Columbia, Canada (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 4,000,000 shares (the “Firm Shares”) of its voting common shares, without par value (the “Common Stock”). The Company also proposes to issue and sell to the several Underwriters up to an additional 600,000 shares (the “Additional Shares”) of Common Stock at the option of the Underwriters as provided in Section 2(c) below. The Firm Shares and any Additional Shares purchased by the Underwriters are referred to herein as the “Shares.” Guggenheim Securities, LLC (“Guggenheim Securities”) is acting as representative (the “Representative”) of the several Underwriters in connection with the offering and sale of the Shares contemplated herein (the “Offering”).
10,526,500 Shares of Common Stock EYEPOINT PHARMACEUTICALS, INC. UNDERWRITING AGREEMENT March 28, 2019Underwriting Agreement • April 1st, 2019 • EyePoint Pharmaceuticals, Inc. • Laboratory analytical instruments • New York
Contract Type FiledApril 1st, 2019 Company Industry JurisdictionEyePoint Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 10,526,500 shares of its common stock (the “Firm Shares”), par value $0.001 per share (the “Common Stock”). The Company also proposes to issue and sell to the several Underwriters up to an additional 1,578,975 shares of Common Stock (the “Additional Shares”) at the option of the Underwriters as provided in Section 2(c) below. The Firm Shares and any Additional Shares purchased by the Underwriters are referred to herein as the “Shares.” Guggenheim Securities, LLC (“Guggenheim”) is acting as representative (the “Representative”) of the several Underwriters in connection with the offering and sale of the Shares contemplated herein (the “Offering”).